Biotronik's absorbable stent shows 1-year promise:
This article was originally published in Clinica
Executive Summary
One-year follow-up data from a clinical trial of Biotronik's absorbable metal stent (AMS) are continuing to support the device, the firm has reported. The European study, which is testing the stent as a treatment for blocked arteries below the knee, revealed that after 12 months there was a primary vessel patency rate of 72.4% and a limb salvage rate of 94.7%. The Berlin, Germany firm said it was now preparing to start a randomised trial called INSIGHT-AMS within the second quarter of this year. The study, which will assess the six-month patency results of patients with infra-popliteal occlusion, is expected to result in Biotronik CE-marking the AMS technology for sale in Europe.